EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor

André Franci iD, Roberto Giraldez iD, Carlos Barbosa, Talia Dalçóquio iD, Paulo Genestreti, Aline Ferrari iD, Fernando Menezes iD, Remo Furtado, Danilo Sarti iD, Luciano Baracioli iD, José Nicolau iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031359 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von André Franci und 10 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo CEP 05403-000, Brazil. Hauptthemen laut MEDLINE: Blood Platelets, Clopidogrel, Platelet Activation, Platelet Aggregation Inhibitors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High platelet reactivity (HPR) in patients with coronary artery disease receiving P2Y12 inhibitors increases ischemic risk. Chronic kidney disease (CKD) is an established contributor to HPR during clopidogrel therapy. The objective of the study was to assess whether CKD influences platelet reactivity (PR) in patients treated with clopidogrel or ticagrelor. This double-blind, double-dummy study enrolled 106 stable patients more than one year after an acute coronary syndrome, with or without CKD. Participants were matched by age and sex and randomized to clopidogrel or ticagrelor. PR was measured using the VerifyNow™ P2Y12 assay, and HPR was defined as P2Y12 reaction units (PRU) ≥ 208. Median glomerular filtration rates were 80 mL/min/1.73 m2 in non-CKD patients and 41 mL/min/1.73 m2 in CKD patients (p < 0.01). Ticagrelor produced similarly low PR in both groups (36 vs. 35 PRU; p = 0.61). Clopidogrel resulted in a numerically higher PR in CKD patients (209 vs. 180 PRU; p = 0.07). The magnitude of PR reduction with ticagrelor relative to clopidogrel was greater in CKD patients (p-interaction = 0.09). HPR was markedly more common with clopidogrel, particularly in CKD (difference 37%; adjusted OR 4.42; p = 0.01). In conclusion, CKD significantly impairs clopidogrel responsiveness but does not affect ticagrelor, resulting in a greater relative advantage of ticagrelor in patients with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsClopidogrelPlatelet ActivationPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRenal Insufficiency, ChronicTicagrelorAgedFemaleHumansMaleMiddle AgedAcute Coronary SyndromeAdenosineDouble-Blind MethodGlomerular Filtration RateReceptors, Purinergic P2Y12Ticlopidine

Stichwörter der Autor:innen

chronic kidney diseaseclopidogrelcoronary artery diseaseplatelet reactivityticagrelor

Substanzen

AdenosineClopidogrelPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12TicagrelorTiclopidine

Autor:innen und Institutionen

  • Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo CEP 05403-000, Brazil.
  • Centro de Cardiologia, Hospital Sírio-Libanês, Sao Paulo CEP 01308-050, Brazil.
  • Hospital do Coracao do Brasil, Brasilia CEP 70390-000, Brazil.
  • Royal College of Surgeons in Ireland, University of Medicine and Heath Sciences-Stephen's Green, D02 YN77 Dublin, Ireland.

ORCID-Profile: André Franci, Roberto Giraldez, Talia Dalçóquio, Aline Ferrari, Fernando Menezes, Danilo Sarti, Luciano Baracioli, José Nicolau

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Franci, A., Giraldez, R., Barbosa, C., Dalçóquio, T., Genestreti, P., Ferrari, A., Menezes, F., Furtado, R., Sarti, D., Baracioli, L., & Nicolau, J. (2026). Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031359

Vancouver

Franci A, Giraldez R, Barbosa C, Dalçóquio T, Genestreti P, Ferrari A, et al. Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031359

BibTeX
@article{Franci2026,
  author = {Franci, André and Giraldez, Roberto and Barbosa, Carlos and Dalçóquio, Talia and Genestreti, Paulo and Ferrari, Aline and Menezes, Fernando and Furtado, Remo and Sarti, Danilo and Baracioli, Luciano and Nicolau, José},
  title = {Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031359}
}
Kostenlos starten →